(-0.08%) 5 304.25 points
(-0.09%) 40 140 points
(-0.05%) 18 465 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(0.21%) $923.00
(0.14%) $0.928
(0.29%) $10.87
(0.01%) $0.792
(0.05%) $92.62
@ $67.25
Issued: 26 Mar 2024 @ 15:46
Return: 1.58%
Previous signal: Mar 26 - 12:12
Previous signal:
Return: -0.03 %
Live Chart Being Loaded With Signals
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia...
Stats | |
---|---|
Today's Volume | 674 974 |
Average Volume | 875 885 |
Market Cap | 7.41B |
EPS | $0 ( 2024-02-27 ) |
Next earnings date | ( $-1.110 ) 2024-05-13 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -16.50 |
ATR14 | $2.14 (3.12%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-25 | Pickering Grant | Buy | 15 000 | Common Stock |
2024-03-25 | Pickering Grant | Sell | 13 450 | Common Stock |
2024-03-25 | Pickering Grant | Sell | 1 550 | Common Stock |
2024-03-25 | Pickering Grant | Sell | 15 000 | Stock Option (Right to Buy) |
2024-03-18 | Guggenhime Andrew | Sell | 8 000 | Stock Option (right to buy) |
INSIDER POWER |
---|
32.16 |
Last 100 transactions |
Buy: 813 250 | Sell: 420 856 |
Volume Correlation
Vaxcyte Inc Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Vaxcyte Inc Correlation - Currency/Commodity
Vaxcyte Inc Financials
Annual | 2023 |
Revenue: | $0 |
Gross Profit: | $-10.17M (0.00 %) |
EPS: | $-4.14 |
Q4 | 2023 |
Revenue: | $0 |
Gross Profit: | $-2.95M (0.00 %) |
EPS: | $-1.900 |
Q3 | 2023 |
Revenue: | $0 |
Gross Profit: | $-2.48M (0.00 %) |
EPS: | $-0.910 |
Q2 | 2023 |
Revenue: | $0 |
Gross Profit: | $-2.40M (0.00 %) |
EPS: | $-0.700 |
Financial Reports:
No articles found.
Vaxcyte Inc
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators